| Identification | Back Directory | [Name]
BML-190 | [CAS]
2854-32-2 | [Synonyms]
IMMA
BML-190
BML-190 USP/EP/BP
BML-190;BML 190;BML190
Indomethacin morpholinamide
INDOMETHACIN MORPHOLINYLAMIDE
Indomethacin Morpholinylamide Impurity
BML 190; BML190; IMMA; INDOMETHACIN MORPHOLINYLAMIDE
N-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetyl]morpholine
4-((2-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl)acetyl)-morpholin
1h-indole,1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-(2-(4-morpholinyl)-2-oxoe
1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-[(morpholinocarbonyl)methyl]-indole
BML-190, N-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetyl]morpholine
2-(1-(4-chlorobenzoyl)-5-Methoxy-2-Methyl-1H-indol-3-yl)-1-Morpholinoethanone
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1-[2-(morpholinyl)-2-oxoethyl]-1H-indole
1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOLE-3-ACETIC ACID, MORPHOLINEAMIDE
1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1-[2-(4-MORPHOLINYL)-2-OXOETHYL]-1H-INDOLE
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-1H-indole
2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-(4-morpholinyl)ethanone
Ethanone, 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-(4-morpholinyl)- | [Molecular Formula]
C23H23ClN2O4 | [MDL Number]
MFCD01317813 | [MOL File]
2854-32-2.mol | [Molecular Weight]
426.89 |
| Chemical Properties | Back Directory | [Melting point ]
162.0-163.5 °C | [Boiling point ]
586.7±50.0 °C(Predicted) | [density ]
1.31 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO: >20mg/mL
| [form ]
solid
| [pka]
-0.97±0.20(Predicted) | [color ]
off-white
|
| Safety Data | Back Directory | [WGK Germany ]
3
| [Toxicity]
rat,LDLo,oral,40mg/kg (40mg/kg),Bollettino Chimico Farmaceutico. Vol. 114, Pg. 309, 1975. |
| Hazard Information | Back Directory | [Uses]
BML-190, is a selective cannabinoid CB2 receptor, and it is also used for treatment of organophosphate and carbamate toxicity. | [Definition]
ChEBI: 2-[1-[(4-chlorophenyl)-oxomethyl]-5-methoxy-2-methyl-3-indolyl]-1-(4-morpholinyl)ethanone is a N-acylindole. | [Biological Activity]
Potent and selective CB 2 receptor ligand (K i values are 435 nM and > 2 μ M for CB 2 and CB 1 respectively). | [References]
[1] new dc, wong yh. bml-190 and am251 act as inverse agonists at the human cannabinoid cb2 receptor: signalling via camp and inositol phosphates. febs lett. 2003 feb 11;536(1-3):157-60. pubmed pmid: 12586356.
[2] chang yh, lee st, lin ww. effects of cannabinoids on lps-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. j cell biochem. 2001;81(4):715-23. pubmed pmid: 11329626.
[3] klegeris a, bissonnette cj, mcgeer pl. reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type cb2 receptor. br j pharmacol. 2003 jun;139(4):775-86. pubmed pmid: 12813001; pubmed central pmcid: pmc1573900.
[4] scutt a, williamson em. cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via cb2 receptors. calcif tissue int. 2007 jan;80(1):50-9. epub 2007 jan 4. pubmed pmid: 17205329.
[5] zhang l, zhang x, wu p, li h, jin s, zhou x, li y, ye d, chen b, wan j. bml-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis. inflamm res. 2008 apr;57(4):157-62. doi: 10. 1007/s00011-007-7141-z. pubmed pmid: 18648754.
[6] zhang q, ma p, cole rb, wang g. in vitro metabolism of indomethacin morpholinylamide (bml-190), an inverse agonist for the peripheral cannabinoid receptor (cb(2)) in rat liver microsomes. eur j pharm sci. 2010 sep 11;41(1):163-72. doi: 10.1016/j.ejps.2010.06.004. epub 2010 jun 11. pubmed pmid: 20542112; pubmed central pmcid: pmc2907062. |
|
|